Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05790122 | Safety and Efficacy of Sutureless Zero Ischemia Laparoscopic Tumor Enucleation for T1 Stage Renal Carcinoma | unknown | — | 146 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03280667 | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma(KEYPAD) | unknown | Phase 2 | 59 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group |
| 1 |
| Mar 29, 2023 |
| clinicaltrials |
| NCT05785052 | Biomarkers of Renal Cancer(BRC) | unknown | — | 1,000 | Biorek S.R.L.INDUSTRY | 2 | Mar 27, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05732857 | Valveless Trocar Versus Standard Trocar in Robot-assisted Complex Partial Nephrectomy | unknown | N/A | 66 | Regina Elena Cancer InstituteOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT05705583 | A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma | unknown | — | 100 | Zhejiang Cancer HospitalOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05638256 | 68Ga-labeled NY104 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05456074 | Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)(IMCOR) | unknown | — | 600 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT02613819 | Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney(FASTRACK II) | unknown | Phase 2 | 71 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT05005195 | Yorkshire Kidney Screening Trial(YKST) | unknown | N/A | 5,850 | University of LeedsOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT04913025 | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers(REFINE) | unknown | Phase 2 | 160 | University College, LondonOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04262427 | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma(CAPER) | unknown | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05440045 | A Clinical Study of 6MW3211 in Patients With Renal Cancer | unknown | Phase 2 | 30 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Aug 17, 2022 | clinicaltrials |
| NCT05243173 | Biomarkers of Response to Systemic Treatments in FH-deficient RCC | unknown | — | 100 | RenJi HospitalOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05485883 | Tislelizumab Plus Lenvatinib in Stage III-IV RCC(TILUR) | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05486871 | Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study. | unknown | N/A | 30 | Sohag UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05426317 | Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression(Onco-PDL1s/B2M) | unknown | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05372302 | Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)(CICERONE) | unknown | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT05154474 | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy(SPACE2) | unknown | — | 150 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT02849535 | Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer(PRISM care) | unknown | N/A | 190 | Hospices Civils de LyonOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04602702 | Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors(PDXovo) | unknown | — | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02994758 | Development of Diagnostics and Treatment of Urological Cancers(DEDUCER) | unknown | N/A | 100 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05262413 | A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | unknown | Phase 1 / Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT03177239 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)(UNISoN) | unknown | Phase 2 | 85 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT04946266 | Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers(MFI2-PREDICT) | unknown | — | 260 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT05170555 | Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617 | unknown | N/A | 40 | Peking Union Medical College HospitalOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT01141816 | Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions | unknown | N/A | 30 | St. Joseph's Healthcare HamiltonOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT02689167 | Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma(SURF) | unknown | Phase 2 | 226 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT05135832 | Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma(PRORECECA) | unknown | N/A | 174 | Herlev and Gentofte HospitalOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05124431 | Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma(ALTER-UC-001) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT05109182 | Virtual 3D Modelling for Improved Surgical Planning of Robotic-assisted Partial Nephrectomy(VISP) | unknown | N/A | 328 | Innersight Labs LtdINDUSTRY | 0 | Nov 5, 2021 | clinicaltrials |
| NCT05068180 | Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients | unknown | Phase 4 | 200 | RenJi HospitalOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT02497599 | Intraoperative Dual-modality Imaging in Renal Cell Carcinoma | unknown | Phase 1 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT01444807 | Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases | unknown | Phase 2 | 132 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04534998 | Robotic-assisted vs. Open Partial Nephrectomy(ROBOCOP) | unknown | Phase 2 | 50 | Universitätsmedizin MannheimOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT04267575 | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites | unknown | N/A | 20 | Jerome Canady, M.D.OTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04995016 | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma(PANDORA) | unknown | Phase 2 | 18 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04177056 | Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief(SOLAR-P) | unknown | N/A | 40 | Hamilton Health Sciences CorporationOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04506671 | Percutaneous Cryoablation Versus Partial Nephrectomy for T1b Renal Tumor | unknown | N/A | 142 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT04958473 | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer(SAARCC) | unknown | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT04891055 | Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)(I-Rene) | unknown | — | 90 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT03624673 | Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatment of T1 Renal Cell Carcinoma | unknown | N/A | 380 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04798963 | The Evaluation of Functional Parenchymal Volume and Split Renal Function Before and After Partial Nephrectomy | unknown | N/A | 60 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04666220 | VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma | unknown | — | 180 | Humanitas Clinical and Research CenterOTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT04714697 | Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma | unknown | Phase 2 | 201 | Asan Medical CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT03738488 | 3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement(3DUrologia) | unknown | N/A | 10 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Jan 15, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Mar 30, 2023source: clinicaltrials